Long-read genome sequencing to help diagnose dystonia
Official title: Evaluation of the Value of Long-read Genome Sequencing for the Molecular Diagnosis of Dystonia: a Prospective Multicenter Study
Run by University Hospital, Strasbourg, France · NCT06999096 · Data updated 2026-11-12
Researchers test long-read genome sequencing to see if it can provide a genetic diagnosis for people with dystonia and related movement disorders when standard tests have not.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 4 sites (Montpellier and 3 other locations) |
| Status | Recruiting |
| Started | April 22, 2026 |
| Main results expected | August 2030 |
| Study ends | August 2030 |
| Registry record updated | May 20, 2026 |
| Trial ID | NCT06999096 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals with familial or early-onset dystonia who have already undergone short-read genome sequencing without a molecular diagnosis, and who have available blood samples from the index case and at least two relatives.
✕Probably not a fit
Patients without a detectable genetic cause or those unable to provide required family samples may not receive a diagnostic benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study uses long-read whole-genome sequencing to detect genetic causes of dystonia in patients and their families who previously had inconclusive results with short-read sequencing. It targets individuals with familial dystonia or early-onset forms, requiring at least two relatives' participation and prior negative short-read testing. The goal is to improve diagnostic yield, inform genetic counseling, and guide prognosis and potential targeted therapies. The study is conducted across multiple French centers with a lead sponsor at University Hospital, Strasbourg, and collaborators at Montpellier, Nancy, and Paris sites.
Why it matters
Potential benefit: If successful, participants may receive a definitive genetic diagnosis that can inform prognosis, family planning, and potential targeted treatment options.
How similar studies have gone: Prior studies suggest that long-read sequencing can uncover variants missed by short-read methods, though the approach is still being evaluated in dystonia.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria - Index case: * Index case affected by familial dystonia (≥1 first-degree relative affected) and/or sporadic early-onset dystonia (symptom onset before age 50), meeting the criteria of the PFMG-2025 program. * Index case who has undergone short-read genome sequencing, which did not lead to a molecular diagnosis. * Ability to understand and sign informed consent by the index case and/or their parents or legal guardians for patients under 18 years of age. * Availability of a blood sample from the index case and at least two relatives, either affected or unaffected. Inclusion criteria - Relatives: * Symptomatic or asymptomatic relative of an index case, who has also undergone short-read genome sequencing without a conclusive molecular diagnosis. * Ability to understand and sign informed consent. Exclusion criteria: * Index case or relatives who are not affiliated with or not beneficiaries of a social security scheme. * Index case and their parents presenting with a condition that, in the opinion of the investigator, would contraindicate participation in the study. * Suspected non-genetic etiology (e.g., perinatal hypoxic-ischemic injury, kernicterus, history of severe head trauma or central nervous system infection).
Where it's running
-
CHRU Nancy
Nancy, France Recruiting -
CHU de Montpellier - Hôpital Gui de Chauliac
Montpellier, France Not yet recruiting -
Hôpital Pitié Salpêtrière- APHP
Paris, France Not yet recruiting -
Hôpitaux Universitaires de Strasbourg
Strasbourg, France Not yet recruiting
Study contacts
- Study coordinator: Thomas WIRTH, Doctor
- Email: thomas.wirth@chru-strasbourg.fr
- Phone: +33 3 88 12 89 19
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Investigating the relationship between genetic mutations and brain changes in dystonia
This study is trying to see how genetic changes linked to dystonia affect the brain in people with the condition compared to healthy individuals.
-
Registry for pediatric deep brain stimulation outcomes
This study is creating a database to collect information on how deep brain stimulation helps children with movement disorders like dystonia and Tourette syndrome, to see how safe and effective the treatment is.
-
Outcomes of radiofrequency ablation for movement disorders
This study looks at how well a specific treatment called radiofrequency ablation works for people with movement disorders like Parkinson's disease and essential tremor.
-
Long-term evaluation of Abbott deep brain stimulation systems for movement disorders
This study is testing how safe and effective Abbott deep brain stimulation systems are for people with movement disorders like Parkinson's disease over a five-year period.
-
Intraoperative Microelectrode Recordings with MAVEN vs Standard Equipment
This study tests whether MAVEN can match the recording data collected during DBS surgery for movement disorders using standard equipment.
-
Low-intensity focused ultrasound for movement and seizure disorders
This trial will try low-intensity focused ultrasound (LIFUS) to see if it can safely change brain activity in people with movement disorders or epilepsy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.